Video

Focusing on Improving Depression in HNC Survivors

Author(s):

Nosayaba Osazuwa-Peters, BDS, MPH, CHES

As cancer survivors are living longer thanks to new treatments, it is essential that health care providers and researchers put more focus on depression.

Now that patients with head and neck cancer (HNC) — as well as many other cancer types – are living much longer, it is essential that researchers and health care professionals recognize the importance of depression and quality-of-life issues, according to Nosayaba Osazuwa-Peters, BDS, MPH, CHES, Instructor, Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine.

Osazuwa-Peters’ recent research shed light on suicide rates in HNC survivors, which he noted were on the rise for all cancer types. Many suicide risk factors, such as depression and pain, are common in survivors, so it is imperative that signs of suicide are recognized in this population so individuals can get the help that they may need.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Image of doctor.
Related Content
Keytruda was approved for locally advanced head and neck cancer before and after surgery: © stock.adobe.com.
June 12th 2025

FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer

Spencer Feldman
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Image of neck.
May 23rd 2025

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

Ariana Pelosci
GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.